Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 25, 2011

Rhenovia Allies with Portmann to Fortify Business in Switzerland

  • French Rhenovia Pharma hopes to forge closer ties with Switzerland’s biopharmaceutical companies, technology suppliers, and financial institutions by teaming up with Swiss company Portmann Instruments. The firms will form a new company or joint venture, whose structure, funding, and modus operandi will be determined before year’s end.

    Under the strategic alliance, Portmann will set up a special unit and laboratory for physico-chemical analysis.The new lab will enable Rhenovia to proceed with the validation of its biosimulation technologies and establish proof-of-concept for its Rhenovia Isoelectric Filtration Technologies (RHIFT)™ platform. RHIFT is designed to identify and track biological markers of the efficacy and side-effects of drugs and reportedly has numerous industrial applications.

    Rhenovia and Portman have partnered since 2008 under a Eurostars program in which Rhenovia was the leader. Eurostars is an EU-funded initiative that provides funds and support to collaborative research and development projects where at least one partner is a small- or medium-sized enterprise or SME.

    Under the collaboration inked today, Portmann will take over prototyping of the advanced transdermal patch developed by the two companies as part of their involvement in Eurostars. Portmann will design the apparatus to be used for feasibility studies and for setting up the pre-industrialization phases.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »